CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs in August 2026

Cytosorbents Corp

Two pre-submission meetings with FDA scheduled for August 2026.
Meetings will cover CytoSorbents' ticagrelor and DOAC programs.
Announcement made at 2026 Life Sciences Forum; no financial impact disclosed.

item 7.01 item 9.01

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-077584

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.